Teresa Kowalska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Teresa Kowalska has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Piotr Richter
Department of Surgery, Jagiellonian Medical University College, Kraków, Poland
6 shared publicationsTomasz Gach
Department of Surgery, Jagiellonian Medical University College, Kraków, Poland
4 shared publicationsAndrzej Rutkowski
Department of Colorectal Cancer, Maria Skłodowska-Curie Memorial Cancer Centre, Warsaw, Poland
3 shared publicationsJan Kulig
3 shared publications- Krzysztof Bujko
Department of Radiotherapy I, M. Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
3 shared publications Krzysztof Paprota
Department of Radiotherapy, St. John's Cancer Center, Lublin, Poland
3 shared publications
Latest Publications
- 1 June 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127 (3) , 396-403
Preoperative radiotherapy and local excision of rectal cancer: Long-term results of a randomised study
- 1 June 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127 (3) , 396-403
Preoperative radiotherapy and local excision of rectal cancer: Long-term results of a randomised study
- Open Access
- 1 January 2014
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 29 (1) , 34-7
Paradoxal metabolic flare detected by 18F-fluorodeoxyglucose positron emission tomography in a patient with metastatic breast cancer treated with aromatase inhibitor and biphosphonate
Patients with estrogen-receptor-positive advanced breast cancer are treated with endocrine therapy. The majority of breast cancer localizations show 18F-fluorodeoxyglucose (FDG) uptake at positron emission tomography (PET) examination. In these patients, the metabolic flare after therapy is common and was proposed as an index of therapy efficacy. Nevertheless, prolonged persistence of flare can lead to misinterpretation. We describe a case of a patient with invasive ductal breast cancer with bone metastases at bone scintigraphy and FDG PET scan and with expression of estrogen receptors. Initially, the patient underwent endocrine therapy in addition to a biphosfonate. Owing to progression observed in a bone scan, Tamoxifen was substituted with aromatase inhibitors. Successive bone scan examinations showed stabilization with a marked clinical improvement. A second FDG PET was performed 28 months after the first examination and showed a metabolic flare phenomenon with concomitant partial calcification of osteolitic lesions. This is an unusual case of prolonged metabolic flare.
- 1 January 2014
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 29 (1) , 34-7
Open AccessParadoxal metabolic flare detected by 18F-fluorodeoxyglucose positron emission tomography in a patient with metastatic breast cancer treated with aromatase inhibitor and biphosphonate
Patients with estrogen-receptor-positive advanced breast cancer are treated with endocrine therapy. The majority of breast cancer localizations show 18F-fluorodeoxyglucose (FDG) uptake at positron emission tomography (PET) examination. In these patients, the metabolic flare after therapy is common and was proposed as an index of therapy efficacy. Nevertheless, prolonged persistence of flare can lead to misinterpretation. We describe a case of a patient with invasive ductal breast cancer with bone metastases at bone scintigraphy and FDG PET scan and with expression of estrogen receptors. Initially, the patient underwent endocrine therapy in addition to a biphosfonate. Owing to progression observed in a bone scan, Tamoxifen was substituted with aromatase inhibitors. Successive bone scan examinations showed stabilization with a marked clinical improvement. A second FDG PET was performed 28 months after the first examination and showed a metabolic flare phenomenon with concomitant partial calcification of osteolitic lesions. This is an unusual case of prolonged metabolic flare.
- 1 February 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 106 (2) , 198-205
Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: A prospective multicentre study
- 1 February 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 106 (2) , 198-205
Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: A prospective multicentre study
- 1 January 2012
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 3, 201-205
Effectiveness of radioisotope therapy in bone metastases, based on personal experience
Aim of the study: Metastatic bone disease is a major clinical and therapeutic problem. It is particularly marked in patients with advanced breast and prostate cancer. Taking into account the diversity of the consequences of skeletal metastases, multidisciplinary patient care should be provided....
- 1 January 2012
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 3, 201-205
Effectiveness of radioisotope therapy in bone metastases, based on personal experience
Aim of the study: Metastatic bone disease is a major clinical and therapeutic problem. It is particularly marked in patients with advanced breast and prostate cancer. Taking into account the diversity of the consequences of skeletal metastases, multidisciplinary patient care should be provided....
- Open Access
- 15 December 2011
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 397 (5) , 801-807
Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer—treatment results at 5-year follow-up
Purpose The purpose of this study was to establish the influence of time interval between preoperative hyperfractionated radiotherapy (5 × 5 Gy) and surgery on long-term overall survival (5 years) and recurrence rate in patients with locally advanced rectal cancer operated on according to total mesorectal excision technique. Methods The treatment group comprised 154 patients with locally advanced rectal cancer who were operated on between 1999 and 2006 in the 1st Department of General Surgery, Jagiellonian University, Cracow, Poland. The data on survival has been systematically collected until 31st of December 2010. In addition, the following aspects were analyzed: the significance of time interval between the end of radiotherapy and surgical treatment and its influence on downsizing, downstaging, rate of curative resections, and sphincter-sparing procedures. Patients were qualified to preoperative radiotherapy 5 × 5 Gy and then randomly assigned to subgroups with different time intervals between radiotherapy and surgery: one subgroup consisted of 77 patients operated on 7–10 days after the end of irradiation, and the second subgroup consisted of 77 patients operated on after 4–5 weeks. Both groups were homogenous in sex, age, cancer stage and localization, distal and circumferential resection margins, and number of resected lymph nodes. Results The 5-year survival rate in patients operated on 7–10 days after irradiation was 63%, whereas in those operated on after 4–5 weeks, it was 73%—the difference was not statistically significant (log rank, p = 0.24). A statistically significant increase in 5-year survival rate was observed only in patients with downstaging after radiotherapy—90% in comparison with 60% in patients without response to neoadjuvant treatment (log rank, p = 0.004). Recurrence was diagnosed in 13.2% of patients. A lower rate of systemic recurrence was observed in patients operated on 4–5 weeks after the end of irradiation (2.8% vs. 12.3% in the subgroup with a shorter interval, p = 0.035). No differences in local recurrence rates were observed in both subgroups of irradiated patients (p = 0.119). The longer time interval between radiotherapy and surgery resulted in higher downstaging rate (44.2% vs. 13% in patients with a shorter interval, p = 0.0001) although it did not increase the rate of sphincter-saving procedures (p = 0.627) and curative resections (p = 0.132). Conclusions 1. Improved 5-year survival rate is observed only in patients with downstaging after preoperative irradiation dose of 25 Gy. 2. Longer time interval after preoperative radiotherapy 25 Gy does not improve the rate of sphincter-saving procedures and curative resections (R0) despite higher downstaging rate observed in this regimen.
- 15 December 2011
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 397 (5) , 801-807
Open AccessRandomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer—treatment results at 5-year follow-up
Purpose The purpose of this study was to establish the influence of time interval between preoperative hyperfractionated radiotherapy (5 × 5 Gy) and surgery on long-term overall survival (5 years) and recurrence rate in patients with locally advanced rectal cancer operated on according to total mesorectal excision technique. Methods The treatment group comprised 154 patients with locally advanced rectal cancer who were operated on between 1999 and 2006 in the 1st Department of General Surgery, Jagiellonian University, Cracow, Poland. The data on survival has been systematically collected until 31st of December 2010. In addition, the following aspects were analyzed: the significance of time interval between the end of radiotherapy and surgical treatment and its influence on downsizing, downstaging, rate of curative resections, and sphincter-sparing procedures. Patients were qualified to preoperative radiotherapy 5 × 5 Gy and then randomly assigned to subgroups with different time intervals between radiotherapy and surgery: one subgroup consisted of 77 patients operated on 7–10 days after the end of irradiation, and the second subgroup consisted of 77 patients operated on after 4–5 weeks. Both groups were homogenous in sex, age, cancer stage and localization, distal and circumferential resection margins, and number of resected lymph nodes. Results The 5-year survival rate in patients operated on 7–10 days after irradiation was 63%, whereas in those operated on after 4–5 weeks, it was 73%—the difference was not statistically significant (log rank, p = 0.24). A statistically significant increase in 5-year survival rate was observed only in patients with downstaging after radiotherapy—90% in comparison with 60% in patients without response to neoadjuvant treatment (log rank, p = 0.004). Recurrence was diagnosed in 13.2% of patients. A lower rate of systemic recurrence was observed in patients operated on 4–5 weeks after the end of irradiation (2.8% vs. 12.3% in the subgroup with a shorter interval, p = 0.035). No differences in local recurrence rates were observed in both subgroups of irradiated patients (p = 0.119). The longer time interval between radiotherapy and surgery resulted in higher downstaging rate (44.2% vs. 13% in patients with a shorter interval, p = 0.0001) although it did not increase the rate of sphincter-saving procedures (p = 0.627) and curative resections (p = 0.132). Conclusions 1. Improved 5-year survival rate is observed only in patients with downstaging after preoperative irradiation dose of 25 Gy. 2. Longer time interval after preoperative radiotherapy 25 Gy does not improve the rate of sphincter-saving procedures and curative resections (R0) despite higher downstaging rate observed in this regimen.
- 1 March 2011
- Published by Elsevier in Lung Cancer
- Vol. 71 (3) , 344-349
Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity
- 1 March 2011
- Published by Elsevier in Lung Cancer
- Vol. 71 (3) , 344-349
Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity
- 1 August 2009
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 92 (2) , 195-201
Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders
- 1 August 2009
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 92 (2) , 195-201
Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders
- 1 November 2008
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 13 (6) , 300-308
Conservative treatment in patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin – assessment of response and toxicity.
SummaryBackgroundCurative treatment options for invasive bladder cancer include radical cystectomy and therapeutic strategies with bladder preservation.AimTo evaluate the toxicity and clinical effectiveness of transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin in muscle invasive bladder cancer.Materials and MethodsBetween October 2005 and March 2008, 27 patients with histologically proven invasive carcinoma of the bladder (T2-4a,N0-1,M0) who were fit for combined radiochemotherapy and refused radical surgery were selected to bladder-sparing protocol.ResultsIn this study, a group of twenty one patients (78%) received two cycles of chemotherapy, and six of them (22%) only one, because of treatment related toxicity. Complete response after finished conservative treatment: transurethral resection, neoadjuvant chemotherapy with gemcytabin and cisplatin, and accelerated hyperfractionated radiotherapy with concomitant boost plus concurrent cisplatin, occurred in 18 patients (67%), partial response in 2 (8%), stable disease in 7(25%). Toxicities for hematologic and nonhematologic parameters during neoadjuvant chemotherapy were acceptable.ConclusionConservative treatment in patients with muscle-invasive bladder cancer provides a high probability of local response with acceptable toxicity in properly selected patients
- 1 November 2008
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 13 (6) , 300-308
Conservative treatment in patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin – assessment of response and toxicity.
SummaryBackgroundCurative treatment options for invasive bladder cancer include radical cystectomy and therapeutic strategies with bladder preservation.AimTo evaluate the toxicity and clinical effectiveness of transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin in muscle invasive bladder cancer.Materials and MethodsBetween October 2005 and March 2008, 27 patients with histologically proven invasive carcinoma of the bladder (T2-4a,N0-1,M0) who were fit for combined radiochemotherapy and refused radical surgery were selected to bladder-sparing protocol.ResultsIn this study, a group of twenty one patients (78%) received two cycles of chemotherapy, and six of them (22%) only one, because of treatment related toxicity. Complete response after finished conservative treatment: transurethral resection, neoadjuvant chemotherapy with gemcytabin and cisplatin, and accelerated hyperfractionated radiotherapy with concomitant boost plus concurrent cisplatin, occurred in 18 patients (67%), partial response in 2 (8%), stable disease in 7(25%). Toxicities for hematologic and nonhematologic parameters during neoadjuvant chemotherapy were acceptable.ConclusionConservative treatment in patients with muscle-invasive bladder cancer provides a high probability of local response with acceptable toxicity in properly selected patients
- 1 September 2007
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 84 (3) , 217-225
Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: Report of a randomised trial
- 1 September 2007
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 84 (3) , 217-225
Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: Report of a randomised trial
- Open Access
- 1 April 2007
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 11 (4) , 520-528
Bromodeoxyuridine Labeling Index as an Indicator of Early Tumor Response to Preoperative Radiotherapy in Patients with Rectal Cancer
- 1 April 2007
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 11 (4) , 520-528
Open AccessBromodeoxyuridine Labeling Index as an Indicator of Early Tumor Response to Preoperative Radiotherapy in Patients with Rectal Cancer